As of 2025-10-16, the Relative Valuation of Arbutus Biopharma Corp (ABUS) is (3.86) USD. This relative valuation is based on P/E multiples. With the latest stock price at 4.47 USD, the upside of Arbutus Biopharma Corp based on Relative Valuation is -186.4%.
The range of the Relative Valuation is (3.10) - (4.47) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 11.0x - 15.8x | 13.7x |
| Forward P/E multiples | 10.9x - 17.3x | 13.6x |
| Fair Price | (3.10) - (4.47) | (3.86) |
| Upside | -169.4% - -200.0% | -186.4% |
| Date | P/E |
| 2025-10-13 | -15.12 |
| 2025-10-10 | -14.52 |
| 2025-10-09 | -15.09 |
| 2025-10-08 | -14.77 |
| 2025-10-07 | -15.16 |
| 2025-10-06 | -15.34 |
| 2025-10-03 | -15.48 |
| 2025-10-02 | -15.87 |
| 2025-10-01 | -16.22 |
| 2025-09-30 | -16.04 |
| 2025-09-29 | -15.76 |
| 2025-09-26 | -15.58 |
| 2025-09-25 | -15.26 |
| 2025-09-24 | -15.87 |
| 2025-09-23 | -15.76 |
| 2025-09-22 | -15.65 |
| 2025-09-19 | -15.02 |
| 2025-09-18 | -15.62 |
| 2025-09-17 | -15.65 |
| 2025-09-16 | -15.55 |
| 2025-09-15 | -16.01 |
| 2025-09-12 | -15.76 |
| 2025-09-11 | -17.31 |
| 2025-09-10 | -16.32 |
| 2025-09-09 | -15.30 |
| 2025-09-08 | -14.45 |
| 2025-09-05 | -14.84 |
| 2025-09-04 | -14.17 |
| 2025-09-03 | -13.89 |
| 2025-09-02 | -13.50 |
| 2025-08-29 | -13.11 |
| 2025-08-28 | -12.97 |
| 2025-08-27 | -12.90 |
| 2025-08-26 | -12.90 |
| 2025-08-25 | -12.37 |
| 2025-08-22 | -12.69 |
| 2025-08-21 | -12.65 |
| 2025-08-20 | -12.33 |
| 2025-08-19 | -12.33 |
| 2025-08-18 | -11.94 |
| 2025-08-15 | -11.89 |
| 2025-08-14 | -11.91 |
| 2025-08-13 | -11.91 |
| 2025-08-12 | -12.01 |
| 2025-08-11 | -11.84 |
| 2025-08-08 | -12.01 |
| 2025-08-07 | -12.01 |
| 2025-08-06 | -12.26 |
| 2025-08-05 | -12.05 |
| 2025-08-04 | -11.80 |